Grow-H – 10mg (CJC-1295 no DAC & Ipamorelin) For Sale

Description

The Science Behind Dual-Pathway GH Stimulation: Why This Combination Works

The CJC-1295/Ipamorelin blend represents a strategic approach to growth hormone research — combining two peptides that work through completely different receptor systems to produce synergistic effects. This dual-pathway design achieves what neither peptide can accomplish alone.

CJC-1295 (No DAC) is a modified GHRH analog that stimulates the pituitary’s growth hormone-releasing hormone receptors. Research demonstrates it normalizes growth in GHRH knockout models and preserves natural pulsatile GH secretion even during continuous stimulation. The “No DAC” formulation (without Drug Affinity Complex) provides shorter-acting effects ideal for controlled research protocols.

Ipamorelin is among the most selective GH secretagogues ever developed — a potent ghrelin/GHS receptor agonist with minimal effects on cortisol, prolactin, or other hormones. Studies have shown it improves bone mineral content, counteracts glucocorticoid-induced bone loss, stimulates pancreatic insulin release, and enhances gastric motility in postoperative ileus models.

When combined, these peptides create a “higher set point” for GH secretion. Ipamorelin raises baseline levels such that CJC-1295 produces both higher peaks and higher troughs — all while maintaining the natural ebb and flow of pulsatile secretion. For research teams investigating GH axis function, bone metabolism, body composition, or metabolic regulation, this blend provides enhanced effects without substantially increased complexity.

For research use only. Not for human consumption.

Dual GH Secretagogue Blend

Two Pathways, One Goal: Synergistic Growth Hormone Research

This blend combines CJC-1295 (No DAC) and Ipamorelin — two peptides that stimulate growth hormone release through distinct but complementary mechanisms. CJC-1295 acts on GHRH receptors while Ipamorelin targets the ghrelin/GHS receptor. Together, they produce synergistic effects that exceed either peptide alone, making this blend essential for comprehensive GH axis research.

10mg total: CJC-1295 (5mg) + Ipamorelin (5mg)
Dual-pathway GH stimulation (GHRH + Ghrelin receptors)
Synergistic effects when combined
Preserves natural pulsatile GH secretion patterns
No DAC formulation for controlled research protocols

For laboratory research use only. Not for human consumption.

Complementary Mechanisms

How Two Peptides Amplify Growth Hormone Release

CJC-1295 stimulates GH release by binding to GHRH receptors on the pituitary — the same pathway used by the body’s natural growth hormone-releasing hormone. Ipamorelin works through a completely different mechanism: it’s a potent agonist of the ghrelin/GHS receptor, one of the most selective GH secretagogues known. This dual-receptor approach raises both baseline GH levels and peak secretion while maintaining natural pulsatile patterns.

CJC-1295: GHRH receptor agonist (pituitary stimulation)
Ipamorelin: Ghrelin/GHS receptor agonist (highly selective)
Raises baseline GH levels (Ipamorelin effect)
Produces higher peaks and troughs (CJC-1295 effect)
Maintains natural pulsatile secretion pattern

For laboratory research use only. Not for human consumption.

Research Applications

From Bone Health to Metabolic Function — Comprehensive GH Research

The CJC-1295/Ipamorelin combination enables research across the full spectrum of GH-mediated effects. Ipamorelin alone has demonstrated benefits for bone health, muscle development, insulin release, and gastric function in animal models. Combined with CJC-1295’s ability to normalize growth in GHRH-deficient models, this blend provides a comprehensive platform for GH axis research.